Prescription Drug Monitoring Program: Guam Territory Profile (2021)

• NCJ Number: 303648
• Date Published: 2021
• Length: 11 pages
• Grant Number(s): 2017–AR–BX–K003
• Agencies: BJA-Sponsored
• Publication Type: Report (Grant Sponsored)

Annotation

The Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP TTAC) reports 2020 data and 2021 features of the Guam Territory PDMP.

Abstract

The acronym of the Guam PDMP is GPDMP, which is administered by the Department of Public Health and Social Services. The email address is provided, with URLs for the PDMP website and related websites for enrollment, query, and data upload. Contact information is provided for the Program Coordinator IV. For 2020, Guam’s population was 168,000, and there were 399 DEA-registered prescribers and 24 DEA-registered dispensers. Fifteen types of reports are issued by the PDMP. The PDMP is funded by the controlled substance registration fees. There is one employee for operations and one for other tasks. A section on policies and procedures includes key dates in the development of the PDMP and information for accessing relevant statutes and rules. Nine types of miscellaneous PDMP capabilities and policies are listed. There is a data retention policy that requires the purging of all information while retaining de-identified data. Training is available for prescribers and dispensers, and it is required for prescribers and dispensers before PDMP use. Information required for PDMP accounts is provided. Law enforcement personnel and agencies are not allowed PDMP accounts. Requests are submitted in writing and require an active case number and approved signature of requestor’s supervisor. Law enforcement access to the  PDMP requires an active investigation and probable cause. Access is through a written request. Criteria for a query are provided in this profile. Dispensers are required to enroll in the PDMP, and prescribers are required to use the PDMP. Veterinarians are exempted from enrollment as data requesters but can voluntarily query. Data monitored or accessible pertain to drugs in Schedules II-V, and there is authority to monitor other substances. Technological capabilities and types of reports are addressed.